Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The year 2025 is characterized by the Chinese medicine industry experiencing a bottoming out phase amid multiple pressures, with both performance and valuation reaching historical lows. The industry faces challenges from demand decline, high base effects, and inventory destocking. Policy impacts include centralized procurement and price governance, which disturb market expectations, leading to a downward shift in price levels and accelerated industry differentiation. The market performance shows that valuations are at historical lows, with institutional allocation ratios dropping to a low point. The year 2026 will see several critical validation points, focusing on policy and inventory cycles as core variables [4][5][9] Summary by Sections 1. Industry Performance in 2025 - The Chinese medicine industry is expected to face a downturn in 2025, with performance under pressure from demand decline, high base effects, and inventory issues. The industry’s revenue for the first three quarters of 2025 is reported at CNY 259.07 billion, a year-on-year decrease of 4.08%, while net profit is CNY 29.499 billion, down 1.46% [15][16][18] 2. Policy Variables - The year 2026 will see significant policy impacts on the Chinese medicine industry, focusing on four dimensions: top-level design for high-quality development, supply-side optimization, normalization of centralized procurement, and adjustments to the essential drug catalog. The release of the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" marks a shift from scale expansion to quality and efficiency improvement, which is expected to enhance the overall competitiveness and sustainability of the industry [5][6][9] 3. Inventory Cycle - After a deep adjustment in 2024-2025, the inventory turnover levels in the Chinese medicine industry are expected to improve gradually. The retail environment is showing signs of recovery, and the adjustment of the essential drug catalog may bring additional demand from hospital channels. The industry is anticipated to gradually clear inventory in 2026, with companies that have high inventory turnover rates and strong brand power likely to recover first [8][9] 4. Investment Strategy - The investment strategy for 2026 emphasizes seeking certainty in alpha through structural differentiation based on core competitiveness. The report recommends focusing on companies with evidence-based medicine, R&D innovation capabilities, quality control advantages, and brand moats. In the hospital market, attention should be paid to the catalytic effects of the essential drug catalog and innovation-driven breakthroughs, while in the external market, recovery driven by inventory stabilization and domestic demand should be monitored [9][10]

Core Viewpoint - The recent implementation of the "Regulations on the Registration Management of Traditional Chinese Medicine" by the National Medical Products Administration is expected to significantly impact the market for traditional Chinese medicine, with a potential exit of many products by 2031 due to stricter requirements for drug registration and safety information [1][2][5]. Group 1: Policy Implementation and Timeline - The new regulations took effect on July 1, 2023, providing a transition period of three years, with an actual deadline for compliance extending to 2031 due to the five-year drug re-registration cycle [1][5]. - Many companies, including leading firms like Yunnan Baiyao and Tongrentang, are already preparing to meet the new requirements by enhancing their product safety information [1][5]. Group 2: Rationale Behind the Policy - The policy aims to improve drug safety by mandating that traditional Chinese medicine products clearly state contraindications, adverse reactions, and precautions, addressing public concerns about medication safety [2][4]. Group 3: Market Impact and Industry Dynamics - The regulations are not expected to lead to a mass exit of traditional Chinese medicine products; instead, they may encourage companies to focus on their core strengths and improve product quality [4][5]. - The Chinese traditional medicine market is characterized by excessive competition, with over 4,500 production companies and approximately 2,400 traditional Chinese medicine enterprises, leading to a potential consolidation as weaker companies may exit the market [5][6]. - The policy could facilitate a shift from a fragmented market to a more robust and high-quality development phase, aligning better with consumer needs [6].